deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03415854

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD)

A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Adenocarcinoma Pancreas Metastases Pancreatic Adenocarcinoma Pancreatic Cancer Pancreatic Ductal Adenocarcinoma
Interventions Paricalcitol (Zemplar)
Updated 15 times since 2018 Last updated: Dec 13, 2023 Started: Jan 31, 2018 Primary completion: Dec 11, 2023 Completion: Dec 11, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adenocarcinoma and Pancreas Metastases and is currently completed. Abramson Cancer Center at Penn Medicine leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Sep 2019 · 10 months · monthly snapshot~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Mar 2022 · 9 months · monthly snapshot~Mar 2022 – ~Apr 2023 · 13 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jan 2024 · 8 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. May 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Mar 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2019 — Sep 2020 [monthly]

    Recruiting PHASE2

  6. Nov 2018 — Sep 2019 [monthly]

    Recruiting PHASE2

  7. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  9. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Feb 2018 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
  • Barts Cancer Institute
  • Cancer Research UK
  • HonorHealth Research Institute
  • Imaging Endpoints
  • Lustgarten Foundation
  • Mayo Clinic
  • Princeton University
  • Salk Institute for Biological Studies
  • Stand Up To Cancer
  • Translational Genomics Research Institute
  • University of California, San Diego
Data source: HonorHealth Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations